West China School of Medicine, Sichuan University.
Department of Gastrointestinal Surgery, West China Hospital, Sichuan University.
Tohoku J Exp Med. 2022 Oct 26;258(3):219-223. doi: 10.1620/tjem.2022.J074. Epub 2022 Sep 1.
Telitacicept is a novel humanized, recombinant transmembrane activator and calcium modulator and cyclophilin ligand interactor and the Fc portion (TACI-Fc) fusion protein, designed to neutralize the activity of both B-cell lymphocyte stimulator (BLyS) and a proliferation-inducing ligand (APRIL). On March 9, 2021, telitacicept received its first approval in China for the treatment of adult patients with active, autoantibody-positive systemic lupus erythematosus (SLE). Additionally, on April 15, 2020, the U.S. Food and Drug Administration (FDA) granted fast track designation to telitacicept for the treatment of SLE. Clinical studies of telitacicept in several other indications, including IgA nephropathy, multiple sclerosis, myasthenia gravis, neuromyelitis optica spectrum disorders, rheumatoid arthritis and Sjögren's syndrome are underway in China. This is the first case that reports telitacicept successfully treated a SLE patient with refractory cutaneous involvement, which provides a potential therapeutic option for recalcitrant cutaneous manifestations of SLE. Furthermore, we review reported studies of BLyS targeted treatments for mucocutaneous lupus. Telitacicept appears to have activity in refractory cutaneous involvement of SLE and clinical trials are warranted to further assess this potential therapy.
替利塞塞普是一种新型人源化、重组跨膜激活剂和钙调节剂及亲环素配体相互作用蛋白 Fc 部分（TACI-Fc）融合蛋白，旨在中和 B 细胞淋巴细胞刺激物（BLyS）和增殖诱导配体（APRIL）的活性。2021 年 3 月 9 日，替利塞塞普在中国首次获批用于治疗活动性、自身抗体阳性的系统性红斑狼疮（SLE）成人患者。此外，2020 年 4 月 15 日，美国食品和药物管理局（FDA）授予替利塞塞普治疗 SLE 的快速通道指定。在中国，替利塞塞普在包括 IgA 肾病、多发性硬化症、重症肌无力、视神经脊髓炎谱系障碍、类风湿关节炎和干燥综合征在内的其他几种适应症的临床试验正在进行中。这是首例报告替利塞塞普成功治疗难治性皮肤受累 SLE 患者的病例，为治疗 SLE 的难治性皮肤表现提供了一种潜在的治疗选择。此外，我们还回顾了 BLyS 靶向治疗黏膜皮肤狼疮的报道研究。替利塞塞普似乎对 SLE 的难治性皮肤受累具有活性，需要进行临床试验来进一步评估这种潜在的治疗方法。
